CLINICAL MEDICAL POLICY

Transcription

1 Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Tysabri (natalizumab) MP-042-MD-WV Provider Notice Date: 10/01/2017 Original Effective Date: 11/01/2017 Annual Approval Date: 09/12/2018 Revision Date: Products: Application: Medical Management; Clinical Pharmacy N/A Page Number(s): 1 of 6 West Virginia Family Health Medicaid All participating hospitals and providers DISCLAIMER West Virginia Family Health medical policy is intended to serve only as a general reference resource regarding coverage for the services described. This policy does not constitute medical advice and is not intended to govern or otherwise influence medical decisions. POLICY STATEMENT West Virginia Family Health may provide coverage under the medical-surgical benefits of the Company s Medicaid products for the medically necessary Tysabri (natalizumab) intravenous administration. This policy is designed to address medical necessity guidelines that are appropriate for the majority of individuals with a particular disease, illness or condition. Each person s unique clinical circumstances warrant individual consideration, based upon review of applicable medical records. The qualifications of the policy will meet the standards of the National Committee for Quality Assurance (NCQA) and all applicable state and federal regulations. DEFINITIONS Progressive Multifocal Leukoencephalopathy (PML) An opportunistic viral infection of the brain that usually leads to death or severe disability. Relapsing-Remitting Multiple Sclerosis (RRMS) Characterized by acute attacks followed by periods of remission; primary form of MS that occurs in approximately 85% of patients. Policy No. MP-042-MD-WV Page 1 of 6

2 Secondary-Progressive Multiple Sclerosis (SPMS) An initial period of RRMS, followed by a steadily progressive course, with or without acute relapses; 75-85% of patients diagnosed with RRMS will transition to SPMS. Progressive-Relapsing Multiple Sclerosis (PRMS) Steadily progressive course from onset with acute attacks, with or without recovery; occurs in less than 5% of MS patients. Crohn s Disease A chronic inflammatory bowel disease that affects both men and women. PROCEDURES 1. Tysabri is considered medically necessary as an intravenous infusion for the treatment of relapsing forms of multiple sclerosis (MS) when the member meets all of the following criteria: A. Patient is 18 years of age and older; AND B. Documentation of a diagnosis of relapsing-remitting or relapsing secondary progressive MS C. The drug is given as monotherapy and not in combination with other therapies approved for the treatment of MS; AND D. Must be prescribed by, or in consultation with, a neurologist or a physician that specializes in the treatment of MS; AND E. Patients initiating therapy for the first time must have at least one clinical relapse documented (e.g., functional disability, hospitalization, acute steroid therapy, etc.) during the prior year; AND F. Therapeutic failure or an inadequate response to two or more medications indicated for the treatment of MS; AND G. Must provide chart documentation demonstrating ongoing monitoring and evaluation of transaminase and bilirubin levels; AND H. Documentation of a baseline MRI scan provided to evaluate for pre-existing progressive multifocal leukoencephalopathy (PML) and done annually while on treatment; AND I. Patient has had anti-jcv antibody testing prior to initiating treatment and annually thereafter J. Coverage provided for situations in which there is functional status that can be preserved. Patient must still either be able to walk at least a few steps or alternatively must have some functional arm/hand use consistent with performing activities of daily living K. Provider, patient and pharmacy must be enrolled in the MS TOUCH REMS Prescribing Program L. Dose must not exceed FDA labeled 300mg infused IV once monthly; AND M. Administration of the medication must be done by a health care provider; AND N. Reauthorization requires documentation of the following: 1) Documentation of a clinical response (decrease in CDAI from baseline); AND 2) No evidence of liver impairment indicated by jaundice or elevated laboratory markers (transaminase, bilirubin); AND 3) No evidence of PML; AND 4) If being prescribed for longer than 2 years, documentation the member has been educated and understands the risk versus benefit of continuing therapy 2. Tysabri is considered medically necessary as an intravenous infusion for the treatment of moderate to severe Crohn s disease when the member meets all of the following criteria: A. Member is 18 years of age or older; AND B. Must be prescribed by, or in consultation with, a gastroenterologist; AND C. The drug is given as monotherapy and NOT being used in combination with immunosuppressants or inhibitors of TNF-α; AND Policy No. MP-042-MD-WV Page 2 of 6

3 D. Patient has had anti-jcv antibody testing prior to initiating treatment and annually thereafter; AND E. Prescriber and member must be enrolled in CD TOUCH REMS Prescribing Program; AND F. Documentation of elevated C-reactive protein (evidence of inflammation) and baseline Crohn s Disease Activity Index 220 (moderate to severe disease); AND G. Must have an inadequate response or intolerance/contraindication to at least 1 medication from each of the following classes: 1) Aminosalicylates (sulfasalazine, mesalamine); OR 2) Corticosteroids (budesonide, prednisone); OR 3) Immunomodulators (Azathioprine, 6-mercaptopurine, methotrexate); OR 4) TNF-α inhibitors (adalimumab, infliximab); AND H. Dose must not exceed FDA labeled 300mg infused IV once monthly; AND I. Administration of the medication must be done by a health care provider; AND J. Reauthorization requires documentation of the following: 1) Documentation of a clinical response (decrease in CDAI from baseline); AND 2) No evidence of liver impairment indicated by jaundice or elevated laboratory markers (transaminase, bilirubin); AND 3) No evidence of PML; AND 4) If being prescribed for longer than 2 years, documentation the member has been educated and understands the risk versus benefit of continuing therapy 3. Contraindications Tysabri is contraindicated in members who have or have had progressive multifocal leukoencephalopathy (PML) and in members who have had a hypersensitivity reaction to Tysabri. 4. When Tysabri is not covered Tysabri is not covered for conditions other than those listed above because the scientific evidence has not been established, including but not limited to: A. Patients with pre-existing hepatic disease or hepatic impairment defined as ALT or AST at least two times the ULN; OR B. Combination use with oral corticosteroids that cannot be tapered off within 6 months of starting Tysabri; OR C. In Crohn s disease, Tysabri should not be used in combination with immunosuppressants or inhibitors of TNF- α Coverage may be provided for any non-fda labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peerreviewed medical literature for treatment of the diagnosis (es) for which it is prescribed. These requests will be reviewed on a case-by-case basis to determine medical necessity. When non-formulary criteria are not met, the request will be forwarded to a Medical Director for review. The physician reviewer must override criteria when, in their professional judgment, the requested medication is medically necessary. 5. Post-payment Audit Statement The medical record must include documentation that reflects the medical necessity criteria and is subject to audit by West Virginia Family Health at any time pursuant to the terms of your provider agreement. Policy No. MP-042-MD-WV Page 3 of 6

4 6. Place of Service The place of service for the intravenous administration of Tysabri is outpatient. GOVERNING BODIES APPROVAL The FDA approved Tysabri on November 23, 2004 as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis. Tysabri increases the risk of PML. When initiating and continuing treatment with Tysabri, physicians should consider whether the expected benefit of Tysabri is sufficient to offset this risk. The FDA approved Tysabri on January 15, 2008 for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn s disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α. CODING REQUIREMENTS Covered Procedure Codes HCPCS Code Description J2323 Solution for Injection, Natalizumab, 300mg/15mL Covered Diagnosis Codes ICD-10 Codes Description G35.0 Multiple Sclerosis (relapsing-remitting) K50.00 Crohn s disease of small intestine with complications K Crohn s disease of small intestine with rectal bleeding K Crohn s disease of small intestine with intestinal obstruction K Crohn s disease of small intestine with fistula K Crohn s disease of small intestine with abscess K Crohn s disease of small intestine with other complications K Crohn s disease of small intestine with unspecified complications K50.10 Crohn s disease of large intestine without complications K Crohn s disease of large intestine with rectal bleeding K Crohn s disease of large intestine with intestinal obstruction K Crohn s disease of large intestine with fistula K Crohn s disease of large intestine with abscess K Crohn s disease of large intestine with other complications K Crohn s disease of large intestine with unspecified complications K Crohn s disease of both small and large intestine with rectal bleeding K Crohn s disease of both small and large intestine with intestinal obstruction K Crohn s disease of both small and large intestine with fistula K Crohn s disease of both small and large intestine with abscess K Crohn s disease of both small and large intestine with other complications K Crohn s disease of both small and large intestine with unspecified complications K50.90 Crohn s disease, unspecified K Crohn s disease, unspecified, with rectal bleeding K Crohn s disease, unspecified, with intestinal obstruction Policy No. MP-042-MD-WV Page 4 of 6

5 K Crohn s disease, unspecified, with fistula K Crohn s disease, unspecified, with abscess K Crohn s disease, unspecified, with other complications K Crohn s disease, unspecified, with unspecified with unspecified complications REIMBURSEMENT Participating facilities will be reimbursed per their West Virginia Family Health contract. POLICY SOURCE(S) Tysabri (Natalizumab) [package insert]. Cambridge, MA: Biogen; 05/2016. Tysabri. In: Micromedex 2.0 online. Ann Arbor, MI. Truven Health Analytics; [2016; accessed 12/13/16.] Disease-modifying treatment of relapsing-remitting multiple sclerosis in adults. Up-to-date, July 2016, accessed July 11, National Multiple Sclerosis Society. Available at: Accessed on July 14, Lichtenstein GA, Hannauer SB, Sandborn WJ, et al. Management of Crohn s Disease in Adults. American College of Gastroenterology Practice Guidelines. Am J Gastroenterol advance online publication, 6 January 2009; doi: /ajg Accessed online on December 15, Terdiman J, Gruss C, Heidelbaugh JJ, et al. American Gastroenterological Association Institute Guideline on the use of thiopurines, methotrexate, and anti TNF-a biologic. Policy History Date Activity 04/21/2017 Initial policy developed 09/12/2017 QI/UM Committee Approval 11/01/2017 Provider effective date Policy No. MP-042-MD-WV Page 5 of 6

6 Policy No. MP-042-MD-WV Page 6 of 6